Methods
A literature search was carried out in PubMed for the
period between January 1st, 2000 and August 30th, 2023.
The syntaxes used were “endometriosis AND matched
AND (art OR assisted reproductive technology OR IVF
OR in vitro fertilization OR ICSI)” (98 papers retrieved)
and “endometrioma AND (unilateral OR contralat -
eral) AND (art OR assisted Reproductive technology
OR IVF OR in vitro fertilization OR ICSI)” (94 papers
retrieved). Only studies providing reliable and unbiased
information on specific steps of the IVF procedure were
considered. Reviews were cited if deemed useful. No
efforts were performed to identify abstracts submitted
to meetings.
Page 4 of 11Somigliana et al. Reproductive Biology and Endocrinology (2023) 21:107
Endometriosis and ovarian response to gonadotropin
stimulation
According to the meta-analysis by Hamdan and co-work-
ers, which included 17 studies for a total of n = 17,593
IVF cycles, a lower mean number of oocytes retrieved
per cycle was demonstrated in women with endome -
triosis compared to controls (mean difference: − 2.0, 95%
CI: − 2.9 to − 1.1) [8]. One is tempted to speculate that
endometriosis per se may reduce the number of oocytes
retrieved.
Notably, when assessing the endometriosis-related
influence on ovarian response, some confounding factors
come into play, including: (i) prior surgery, which can
affect ovarian reserve and responsiveness to stimulation;
(ii) the incompleteness of oocyte retrieval. Regarding this
latter point, physicians are generally concerned by the
risk of endometrioma infection during oocytes retrieval
and tend to avoid endometrioma transfixion. Moreover,
due to endometriosis, ovaries may be dislocated in the
pelvis, making the retrieval more difficult (Fig. 1) [12].
Accordingly, the frequency of incomplete follicular aspi -
ration was found to be over three times more common in
affected women [27].
Insights from a rigorous matching design
To provide an unbiased evaluation of ovarian responsive-
ness in women with endometriosis, we have designed
a study where n = 248 women with endometriosis and
an adequate ovarian reserve (AMH > 1.1 ng/ml) were
meticulously matched to n = 248 controls, according to
age, pharmacological regimen (same drug, same initial
Fig. 1 Key confounders in different steps of the IVF procedure that could influence study results on the impact of endometriosis. WOI: Window
of Implantation; ICSI: Intracytoplasmic sperm injection
Page 5 of 11
Somigliana et al. Reproductive Biology and Endocrinology (2023) 21:107
dose), AMH concentration and study period [23]. Prior
surgery for endometriosis or the presence of ovarian
endometriomas were not exclusion criteria. This study
design aimed to furnish an unbiased understanding of
endometriosis’s effect on ovarian response. To concomi-
tantly assess quantitative and qualitative aspects of the
ovarian response, our primary outcome was the unavail -
ability of good quality embryos on day 3 (not pregnancy
rates as this might be influenced by the concomitant
presence of adenomyosis). The rate of unexpected poor
response (retrieval of ≤ 3 oocytes) according to the Posei-
don Group (2016) as well as the overall success rate were
secondary outcomes [28]. Results obtained showed that
the number of women without good quality embryos did
not differ between women with and without endometrio-
sis (16% in both groups). However, in women with endo -
metriosis, the duration of stimulation was longer, and the
number of oocytes retrieved (but not mature oocytes)
was lower. The rate of unexpected poor response to ovar-
ian stimulation differed being 13% in non-affected cases
versus 23% in controls (p = 0.005). Notably, in subgroup
analyses, such higher rate of unexpected poor respond -
ers persisted only in women who had undergone sur -
gery for the disease. All other variables related to ovarian
response showed no notable difference (results are pre -
sented in Fig. 2).
Albeit being a secondary outcome, it is worth noting
that the cumulative clinical pregnancy and live birth rates
were almost identical, even slightly favouring the endo -
metriosis group (50% and 40% in endometriosis patients,
and 49% and 36% in controls, respectively). Taken
together, results from this study suggest that endometrio-
sis per se does not have a major impact on folliculogene -
sis. The observed detrimental effect of surgery on the risk
of unexpected poor response may reflect an increased
difficulty in the oocyte retrieval procedure.
Another matched study published in 2017 should also
be mentioned, although the sample size was smaller and
the matching less scrupulous [29]. The authors retro -
spectively matched n = 119 women who had undergone
surgery for endometriosis to a control group of n = 119
women without the disease by age, serum AMH, number
of previous cycles and method of fertilization (conven -
tional IVF or ICSI). The number of oocytes retrieved, and
the number of good quality embryos were comparable.
The live birth rate per cycle was also similar (27% vs 30%)
[29].
The impact of ovarian endometriomas
The impact of endometriomas on ovarian response rep -
resents a related but independent issue. Several intra-
patient comparisons between the two gonads (affected
versus unaffected) have been performed to determine if
unilateral ovarian endometriomas could affect ovarian
response in women on ART cycles who had not previ -
ously had ovarian surgery [8, 12, 30–33]. These studies
generally suggest that the presence of these cysts does
not significantly impact ovarian response. Only one of
these studies was prospective and reported also data on
oocytes quality [34]. The number of developed follicles
Fig. 2 Box and whiskers plot of the number of follicles, oocytes retrieved, suitable oocytes, 2PN (fertilized oocytes), cleavage embryos and good
quality embryos. Data from women with and without endometriosis are represented in red and green, respectively. A statistically significant
difference emerged only for the number of oocytes retrieved (highlighted with an asterisk)
Page 6 of 11Somigliana et al. Reproductive Biology and Endocrinology (2023) 21:107
and oocytes retrieved were similar, being 3.7 ± 2.4 and
4.1 ± 1.7, and 4.2 ± 3.1 and 4.7 ± 2.5, respectively in the
two ovaries. Fertilization and cleavage rates, and rate of
high-quality embryos did not differ, being 64% and 64%,
58% and 51%, and 31% and 21%, respectively. However,
the limited sample size (n = 29) and the small mean diam-
eter of the endometriomas (25 ± 9 mm) hindered strong
conclusions.
For bilateral endometriomas, three retrospective stud -
ies could be mentioned, of which one was very small
(only n = 13 women) and not matched [35]. The second
study, from our group, included n = 39 cases and n = 78
controls matched in a 1:2 ratio for age and study period
[36]. Despite similar biomarkers of ovarian reserve, the
number of follicles > 15 mm and oocytes retrieved were
fewer in women with bilateral endometriomas compared
to controls, being 6.2 ± 2.6 and 9.6 ± 4.8 (p < 0.001) and
7.1 ± 3.2 and 9.8 ± 5.5 (p = 0.001), respectively [36]. How -
ever, the cumulative live birth rate did not significantly
differ, being 25% and 31%, respectively [36]. A third
matched study enrolling n = 70 women with unoperated
endometriomas, of whom n = 38 had bilateral cysts, failed
to show any significant difference in serum AMH levels
or number of embryos obtained. Notably, a subgroup
analysis specifically focusing on these n = 38 women with
bilateral endometriomas and their n = 38 matched con -
trols was not reported [37].
A neglected but crucial aspect that could explain these
inconsistencies is the size of the endometrioma. Sev -
eral studies that examined the intra-patient compari -
son of ovarian response among women with unilateral
endometriomas presented subgroup secondary analyses
based on cyst diameter, suggesting a detrimental effect
based on the cyst dimension [22, 38]. In general, firm
Conclusion
could not be drawn because of the insuffi -
cient number of large endometriomas included and the
nature of these analyses being secondary or exploratory.
Ferrero et al. (2017) were the first to selectively focus
on women with unilateral endometriomas larger than
5 cm. The intra-patient comparison showed a significant
decline in ovarian response with a lower number of fol -
licles in ovaries with endometriomas (2.6 ± 1.3) compared
to healthy ovaries (4.8 ± 2.0; p < 0.001). Since the number
of oocytes retrieved was recorded separately for the two
ovaries, they were also able to report a marked difference
between the affected and unaffected ovaries, which was
1.5 ± 1.1 and 3.3 ± 1.5, respectively (p < 0.001) [31].
A multicenter international study was then set aiming
to identify the threshold of diameter above which ovar -
ian response starts to be critically impaired [32]. The
authors retrospectively included unoperated women
carrying unilateral endometriomas with a mean diam -
eter between 20 and 49 mm, and categorized them based
on endometrioma size: 20–29 mm, 30–39 mm, and
40–49 mm. A negative effect on the number of devel -
oping follicles was observed only for cysts with a mean
diameter from 40 to 49 mm. The median [interquartile
range – IQR] number of developed follicles was 5 [3–7]
and 7 [4–8] in affected and not affected ovaries, respec -
tively (p = 0.01). These results suggest that a threshold of
4 cm might be used to discriminate between cysts that do
and do not affect ovarian responsiveness [32].
Finally, a rather popular but poorly investigated aspect
is represented by the possibility that the potential detri -
mental effect of endometriomas on ovarian reserve and
response to gonadotropin might be progressive over time.
In other words, recently developed ovarian endometrio -
mas might initially present little to no issues whereas
long-lasting lesions might pose significant risks. The
biological plausibility supporting this view stems from
the fact that ovarian endometriomas contain a plethora
of potentially toxic agents. The long-lasting diffusion of
these substances into the ovarian stroma may progres -
sively damage and diminish the primordial follicular
pool [39]. However, from the clinical point of view, this
issue is controversial. Kasapoglu and coauthors repeated
AMH testing at 6 months apart in n = 40 women with
endometriomas (mean diameter 46 ± 17 mm, bilateral
in 9 subjects) and n = 40 controls. They observed a sta -
tistically significant reduction of 26% (95% CI: 11–55%)
in the formers, but no significant changes in the controls
[40]. In contrast, we set up a study to retrospectively
weight this aspect in women with endometriomas (aver -
age diameter of 26 ± 8 mm), who underwent more than
one cycle of ovarian stimulation at intervals of more than
6 months (median 11 months, IQR 8–14 months). The
contribution of the affected ovary to the overall response
in terms of number of follicles retrieved remained con -
sistent across cycles and equal to 44% (31–58%) during
the first cycle and 44% (35–55%) in subsequent cycles
[41]. From these two studies, we may infer that while the
detrimental effects of endometriomas over time is unre -
markable for small cysts, it could be significant for larger
cysts.
Endometriosis and levels of steroid hormones
According to Barnhart and coauthors, women with endo-
metriosis have a 19% reduction of peripheral of estrogen
levels at the time of ovulation trigger [7], suggesting an
altered steroidogenesis. Some molecular studies support
a negative influence of endometriosis on growth, steroi -
dogenic activity, and function of granulosa cells [42]. In
affected women, both granulosa cell expression of P450
aromatase (an enzyme that converts androgens to estro -
gen) and estrogen concentrations in the granulosa cell
culture mediums were found to be reduced [43].
Page 7 of 11
Somigliana et al. Reproductive Biology and Endocrinology (2023) 21:107
However, when interpreting these findings, one cannot
exclude a confounding effect arising from reduced ovar -
ian reserve, at least when addressing evidence from clini -
cal studies. The above-mentioned study from Invernici
and co-authors (2020), who carefully matched cases and
controls for ovarian reserve, tends to reject the hypoth -
esis of perturbed folliculogenesis. The serum estradiol at
the time of trigger was identical, the median [IQR] being
1837 [1283–2831] and 1901 [1341–2811] pg/ml in cases
and controls, respectively [23]. Reschini and co-authors
(2020) designed a study specifically tailored to address
this issue. Matching n=53 cases and n=53 controls by
study period, age, total number of developed follicles,
protocol of ovarian stimulation, type and starting dose of
gonadotropin, they reported similar median [IQR] serum
estrogens of 1586 [1146–2787] and 1625 [1060–2322]
pg/ml, respectively [26]. Overall, available clinical evi -
dence challenges the data from basic science studies [42].
Ovarian steroidogenesis does not seem to be affected in
women with endometriosis, further supporting the idea
that the disease might have minimal, if any, impact on
oocyte quality.
Endometriosis and fertilization rate
Although the number of studies included was very lim -
ited, some meta-analyses reported a reduced fertiliza -
tion rate per oocyte in women with endometriosis [4, 5].
According to Horton and co-workers (2019), this find -
ing is significant for treated patients (OR 0.92, 95% CI:
0.86–0.99, p = 0.03) but not for those untreated [5]. Fer -
tilization rate seems to be more compromised in case of
milder endometriosis presentations. Though, the estima -
tion of the fertilization rate in affected cases is as well not
devoid of confounding factors.
Previous studies have retrospectively compared results
between ICSI and conventional IVF (c-IVF) in women
with endometriosis [43]. This was based on the assump -
tion that endometriosis itself might be responsible for
a reduced oocyte competence so that ICSI, rather than
c-IVF, could overcome this oocyte impairment. Compar -
ing sibling oocytes, Komsky-Elbaz et al. have reported a
higher fertilization rate when ICSI was preferred rather
than c-IVF in couples with stages III–IV endometriosis
[43]. However, possible biases in the analysis should be
kept in mind, including: (i) maturity of oocytes is rou -
tinely established in case of ICSI and this selection bias
may contribute to a higher fertilization rate per oocyte
compared with unselected oocytes undergoing c-IVF;
(ii) the common tendence to prefer ICSI in cases of male
infertility but also to avoid total fertilization failure.
A more accurate approach for the correct assess -
ment of this parameter would be a comparison of the
fertilization rate of oocytes from women with and
without endometriosis by means of the same insemina -
tion approach. Along this line, the above-mentioned
study from Shebl et al. is of great interest because the
authors ensured matching based on the fertilization pro -
cedure used [29]. They observed comparable fertilization
rates for women requiring ICSI and a slightly lower rate
among those endometriosis women treated with c-IVF
(45% versus 54%, p = 0.03). Again, a potential bias could
be introduced as the analysis was performed per oocyte
(and not per woman). In a recent matched case–control
study, we have demonstrated that a diagnosis of endo -
metriosis does not negatively affect the performance of
c-IVF [29]. Three-hundred and fourteen patients with
endometriosis and normozoospermic partners have been
matched in a 1:1 ratio with patients undergoing IVF for
other indications, with respect to age (± 6 months), num-
ber of oocytes retrieved (± 1), and study period. The fer -
tilization rates did not differ between women with and
without endometriosis (median [IQR] being 78% [60–
100%] and 75.0% [56–90%]; p = 0.24, respectively) [24].
A similar approach should be adopted for ICSI in endo -
metriosis patients with also a male infertility factor to
prove that the fertilization rate is not substantially com -
promised in women with endometriosis requiring ICSI.
To date, it can be reasonably inferred that endometriosis
does not impact the performance of c-IVF.
Endometriosis and embryo quality and ploidy
The assessment of embryo morphology and ploidy rate
in women of endometriosis, as a measure to quantify the
impact of the disease on ART outcomes, is not devoid
of problems. Firstly, morphological features are charac -
terized by differences in the criteria adopted to evaluate
embryo quality, leading to inconsistencies across studies.
Furthermore, both embryo morphology and ploidy seem
to be at some extent affected by the ovarian reserve and
the dose/duration of gonadotrophin regimen used for
ovarian stimulation [44]. This leads to the idea that retro-
spective studies addressing this question may have been
confounded by the possible inclusion of affected women
who have undergone surgery. Despite these possible limi-
tations and confounders, a recent meta-analysis based on
22 studies, specifically addressing high embryo quality
rate as main outcome measure, did not show any nega -
tive impact of endometriosis [45]. Women with endome -
triosis, including severe stages and endometriomas had
similar rates of embryo formation, cleavage embryos and
high-quality embryos rates compared with the control
group [45].
Sanchez et al. analysed n = 429 ART cycles in women
undergoing surgery for moderate/severe stages and
compared them with n = 851 cycles in control patients
matched for age, number of oocytes retrieved and study
Page 8 of 11Somigliana et al. Reproductive Biology and Endocrinology (2023) 21:107
period [46]. No differences were reported in terms of
number of cleavage stage embryos and proportion of
good/fair quality embryos. In contrast, this study docu -
mented a reduced likelihood of pregnancy in the endo -
metriosis group, which may be explained by the higher
doses of gonadotropins required in the endometriosis
group to achieve the same number of oocytes [19, 20].
Furthermore, the conclusions of this study are limited
by the inclusion of cycles adopting only cleavage stage
embryo transfer strategy, the exclusion of cycles where
no embryo was obtained or all embryos were cryopre -
served, and by limited attention given to the selection of
controls.
Going further, Vaiarelli and coworkers have evaluated
the euploid blastocyst rate per cohort of inseminated
metaphase II oocytes [47]. Affected patients (n = 210)
were matched in a 1:2 ratio to controls (n = 420) by
IVF clinic, maternal age at retrieval, number of previ -
ous failed IVF treatments and number of metaphase II
oocytes retrieved. The blastocyst rate and the embryo
euploid rate per cohort of fertilized oocytes was similar
between cases and matched controls, even if the blasto -
cyst morphology was not considered.
Only two other studies have examined the euploid rate
of embryos from patients with endometriosis. Results are
controversial. In 2017, Juneau et al. retrospectively ana -
lysed the aneuploidy rate of 1880 blastocysts obtained
from patients with endometriosis and compared them
with 23,054 blastocysts from age-matched controls. They
reported similar aneuploidy rates per biopsied blasto -
cyst in the two groups [48]. In disagreement, Yan and
coworkers, evaluating 7092 biopsied embryos, found a
lower euploid embryo rate in women with endometrio -
mas compared to controls (53% vs. 62%, p = 0.012) [49].
However, in this latter study, the statistical differences
between the two groups in terms of total and starting
dose of gonadotrophins used and FSH levels, question
its absence of confounding factors. In this regard, based
on the study design employed, results from Vaiarelli and
coworkers seem the most robust [47].
Endometriosis and embryo implantation rate
Embryo implantation potential is one of the most
debated aspects of endometriosis-related infertility and
IVF failure. An altered receptivity was advocated as a
main reason for the lower pregnancy rate in women with
endometriosis, beyond the lower ovarian reserve. A bur -
den of literature has documented molecular and cellular
alterations in the eutopic endometrium of women with
endometriosis. These molecular pathways can be broadly
classified into several groups including epigenetic modi -
fiers, immune response regulators and inflammation trig-
gers, hormonal stress inducers, epithelial-mesenchymal
transition modulators [50]. Given these premises, it has
been hypothesized that the communication between
embryo and endometrium could be impaired, increas -
ing the risk of implantation failure [51]. The inflam -
matory milieu of the pelvis has also been supposed to
have some echoes in the endometrial cavity (secondary
event). Regardless of the pathogenetic pathways leading
to altered endometrium (i.e., whether they are primary
or secondary of the disease, or both), ART is not the
solution for these detrimental mechanisms. ART treat -
ments can overcome most of the anatomic and functional
impairment of the reproductive system, but they cannot
heal the supposed molecular endometrial alterations.
Notably, measuring endometrial receptivity is the
most challenging step in case of endometriosis. Embryo
implantation is influenced by two main confounding fac -
tors. First, the low ovarian reserve reduces the rate of
optimal embryos to transfer. In addition, poor respond -
ers are at higher risk of early progesterone elevation [52,
53], a condition that displace the window of implantation,
therefore interfering with embryo implantation [54]. Sec-
ond, endometriosis is associated with conditions that per
se interfere with implantation, including adenomyosis,
polyps and endometritis [3, 55–57]. Endometrial polyps
and chronic endometritis are thought to exert a negative
effect on endometrial receptivity [55, 57–59]. Adenomy -
osis is thought to prompt both uterine hyperperistalsis
and fibrosis through epithelial-to-mesenchymal transi -
tion and fibroblast-to-myofibroblast transdifferentiation.
Notably, the number of microvilli is reduced, steroid
hormone metabolism is altered, and oxidative stress is
increased in the endometrium of women with adenomy -
osis [3].
Clinical studies specifically designed to investigate the
detrimental effect of the disease on endometrial receptiv-
ity are therefore difficult to conduct [59–63]. Analysing
data derived from the ‘freeze all’ strategy could represent
a way to eliminate some of the confounders. In a retro -
spective Chinese cohort study based on more than n=400
endometriosis patients undergoing frozen embryo trans -
fer after ART treatments, affected patients were matched
in a 1:3 rate with women undergoing ART due to tubal
factor-related infertility, considering their age, infertil -
ity duration, serum FSH levels, antral follicular count,
and BMI. Results obtained showed that endometriosis
patients have lower live birth rate per transfer, as well as
lower cumulative live birth rate, compared to controls
[63]. However, the number of oocytes retrieved was sig -
nificantly lower in affected women. As already discussed
[46], this may affect the chance of pregnancy because
embryos obtained with higher doses of gonadotropins or
lower number of oocytes are at higher risk of aneuploidy.
Accordingly, Blank et al. also observed a detrimental
Page 9 of 11
Somigliana et al. Reproductive Biology and Endocrinology (2023) 21:107
effect on pregnancy rates when comparing fresh transfers
between women with and without endometriosis, after
matching them for study period, age, parity, and embryo
quality [62]. However, the number of retrieved oocytes
were again significantly lower among women with endo -
metriosis, as well as the rate of c-IVF (controls predomi -
nantly resorting to ICSI due to male factor infertility).
Not surprisingly, other studies present differing views.
Bishop et al. evaluated the implantation trend in three
populations undergoing euploid frozen embryo transfer
after ART treatments for different indications, including
endometriosis, male factor, and preimplantation genetic
testing for monosomic disorders. This study design over -
comes the limitations of the three beforementioned stud-
ies. No difference in pregnancy outcomes, including live
birth rate, were found across the groups [61]. Zimmer -
mann et al. recently compared n = 195 women who had
undergone surgery for stage III-IV endometriosis to a
control group matched for age, BMI, serum AMH, and
number of previous cycles. The observed cumulative
live birth rates were 32% and 37%, respectively (p = 0.24)
[64]. Finally, our group has recently set up a matched
case–control study (n = 101 per group) with the aim to
compare ART outcomes following single frozen embryo
transfers between women with and without moderate/
severe endometriosis. Remarkably, case and controls are
matched not only for age, but also for number and qual -
ity of blastocysts obtained. The cumulative live birth rate
per cycle did not vary between the two groups (affected:
51% vs healthy: 58%, p = 0.32) supporting a limited, if any
effect of the disease on endometrial receptivity [25].
Even more interestingly, some studies have evaluated
whether endometriosis would be responsible for a sup -
posedly low implantation rate when they are recipients
of donor oocytes. A retrospective study assessed the
cumulative pregnancy rates in more than 10,000 oocyte
donation cycles over a 10-year period. Recipients with
endometriosis had similar cycle outcomes compared to
other oocyte recipient groups, who received oocytes for
other infertility indications, such as low ovarian response,
recurrent ART treatments failure, or advanced age [65].
Overall, the concept that the uterine environment could
be responsible for affecting the implantation process in
women with endometriosis is challenged by the previous
findings.
Concluding remarks
While endometriosis remains an enigmatic disease
from the aetiology standpoints, the mechanisms under -
lying its consequences on fertility and pain perception
are currently better characterized. As our knowledge
increases, factors that may interfere with the objective
and accurate assessment of the clinical consequences
of endometriosis are emerging. In this context, it is
becoming evident that meta-analytic data of obser -
vational studies are not always reliable. Synthesising
observational studies can lead to a high risk of within-
study and across-study biases, as well as to the presence
of increased heterogeneity [66].
To overcome these difficulties, we have herein reviewed
available evidence on the relation between endometriosis
and IVF outcomes, unpacking each step of the process,
prioritizing intra-patient comparisons (that are highly
informative for unilateral endometriomas) and matched
studies. To note, the method of matching differed accord-
ing to the specific aspect of the IVF procedure that one
aimed to investigate. The main conclusions that could be
disentangled from our effort are the following:
1. Endometriosis is unremarkable to ovarian response.
A reduction in the response to ovarian stimulation
can be detected only for endometriomas larger than
4 cm. The follicular steroidogenesis is unaffected.
2. Oocyte quality is preserved. Fertilization rate is simi -
lar, making ICSI unjustifiable. Embryological devel -
opment does not differ from other forms of infertil -
ity, with no surge in aneuploidy rate.
3. Endometrial receptivity is not or minimally reduced.
To note, the most informative studies supporting this
perspective did not exclude women with adenomyo -
sis, a main confounder that was expected to lower
the success of the procedure. This further strength -
ens the idea that women with endometriosis should
not be considered at increased risk of implantation
failure. However, our selected evidence does not
allow us to draw any conclusion on women with
most advanced and disrupting forms of adenomyosis.
These cases are rare, and the selected studies cannot
be used to conclude that adenomyosis is unremark -
able.
In conclusion, our review suggests that endometrio -
sis does not affect IVF outcomes. Deciding different
regimens of treatment or different laboratory protocols
solely based on the diagnosis of endometriosis is not
justified. On the other hand, it must be reminded and
emphasized that the present review investigated pos -
sible sources of impairment beyond the damage to the
ovarian reserve. In fact, the main relevant challenge in
infertile women with endometriosis undergoing IVF is
the prevention of surgically induced ovarian damage.
Authors’ contributions
All authors were actively involved in the preparation of the manuscript (con-
ceptualization: E.S., P .Vi..; manuscript and figure preparation: E.S., L.L.P ., A.P ., N.S.,
P .Vi; manuscript review: L.B., M.O., P .Ve.).
Page 10 of 11Somigliana et al. Reproductive Biology and Endocrinology (2023) 21:107
Funding
This study was funded by the Italian Ministry of Health — Current research
IRCCS.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
E.S. declares honoraria and grants from Theramex, Merck-Serono and Ferring.
P .V. is a Section Editor of Reproductive Biology and Endocrinology. All the
other authors have nothing to declare.
Received: 21 September 2023 Accepted: 26 October 2023
References
1. de Ziegler D, Borghese B, Chapron C. Endometriosis and infertility: patho-
physiology and management. Lancet. 2010;376(9742):730–8.
2. Somigliana E, Vigano P , Benaglia L, Busnelli A, Berlanda N, Vercellini P .
Management of endometriosis in the infertile patient. Semin Reprod
Med. 2017;35(1):31–7.
3. Vercellini P , Viganò P , Bandini V, Buggio L, Berlanda N, Somigliana E. Asso-
ciation of endometriosis and adenomyosis with pregnancy and infertility.
Fertil Steril. 2023;119(5):727–40.
4. Harb HM, Gallos ID, Chu J, Harb M, Coomarasamy A. The effect of
endometriosis on in vitro fertilisation outcome: a systematic review and
meta-analysis. BJOG. 2013;120(11):1308–20.
5. Horton J, Sterrenburg M, Lane S, Maheshwari A, Li TC, Cheong Y. Repro-
ductive, obstetric, and perinatal outcomes of women with adenomyosis
and endometriosis: a systematic review and meta-analysis. Hum Reprod
Update. 2019;25(5):592–632.
6. Hamdan M, Omar SZ, Dunselman G, Cheong Y. Influence of endometrio-
sis on assisted reproductive technology outcomes: a systematic review
and meta-analysis. Obstet Gynecol. 2015;125(1):79–88.
7. Barnhart K, Dunsmoor-Su R, Coutifaris C. Effect of endometriosis on
in vitro fertilization. Fertil Steril. 2002;77(6):1148–55.
8. Hamdan M, Dunselman G, Li TC, Cheong Y. The impact of endometrioma
on IVF/ICSI outcomes: a systematic review and meta-analysis. Hum
Reprod Update. 2015;21(6):809–25.
9. Younis JS, Shapso N, Ben-Sira Y, Nelson SM, Izhaki I. Endometrioma sur-
gery-a systematic review and meta-analysis of the effect on antral follicle
count and anti-Müllerian hormone. Am J Obstet Gynecol. 2022;226(1):33-
51.e7.
10. Nankali A, Kazeminia M, Jamshidi PK, Shohaimi S, Salari N, Mohammadi
M, Hosseinian-Far A. The effect of unilateral and bilateral laparoscopic
surgery for endometriosis on Anti-Mullerian Hormone (AMH) level after
3 and 6 months: a systematic review and meta-analysis. Health Qual Life
Outcomes. 2020;18(1):314.
11. Moreno-Sepulveda J, Romeral C, Niño G, Pérez-Benavente A. The effect
of laparoscopic endometrioma surgery on anti-müllerian hormone: a
systematic review of the literature and meta-analysis. JBRA Assist Reprod.
2022;26(1):88–104.
12. Somigliana E, Benaglia L, Paffoni A, Busnelli A, Vigano P , Vercellini P . Risks
of conservative management in women with ovarian endometriomas
undergoing IVF. Hum Reprod Update. 2015;21(4):486–99.
13. Benaglia L, Somigliana E, Vighi V, Ragni G, Vercellini P , Fedele L. Rate of
severe ovarian damage following surgery for endometriomas. Hum
Reprod. 2010;25(3):678–82.
14. Busacca M, Riparini J, Somigliana E, Oggioni G, Izzo S, Vignali M, Candiani
M. Postsurgical ovarian failure after laparoscopic excision of bilateral
endometriomas. Am J Obstet Gynecol. 2006;195(2):421–5.
15. Polyzos NP , Drakopoulos P , Parra J, Pellicer A, Santos-Ribeiro S, Tournaye
H, Bosch E, Garcia-Velasco J. Cumulative live birth rates according to the
number of oocytes retrieved after the first ovarian stimulation for in vitro
fertilization/intracytoplasmic sperm injection: a multicenter multinational
analysis including ∼15,000 women. Fertil Steril. 2018;110(4):661-670.e1.
16. Muzii L, Di Tucci C, Di Feliciantonio M, Galati G, Di Donato V, Musella A,
Palaia I, Panici PB. Antimüllerian hormone is reduced in the presence of
ovarian endometriomas: a systematic review and meta-analysis. Fertil
Steril. 2018;110(5):932-940.e1.
17. Horne AW, Missmer SA. Pathophysiology, diagnosis, and management of
endometriosis. BMJ. 2022;14(379):e070750.
18. Ragni G, Somigliana E, Benedetti F, Paffoni A, Vegetti W, Restelli L,
Crosignani PG. Damage to ovarian reserve associated with laparoscopic
excision of endometriomas: a quantitative rather than a qualitative injury.
Am J Obstet Gynecol. 2005;193(6):1908–14.
19. Baart EB, Martini E, Eijkemans MJ, Van Opstal D, Beckers NG, Verhoeff A,
Macklon NS, Fauser BC. Milder ovarian stimulation for in-vitro fertilization
reduces aneuploidy in the human preimplantation embryo: a rand-
omized controlled trial. Hum Reprod. 2007;22(4):980–8.
20. van Tilborg TC, Torrance HL, Oudshoorn SC, Eijkemans MJC, Koks CAM,
Verhoeve HR, Nap AW, Scheffer GJ, Manger AP , Schoot BC, Sluijmer AV,
Verhoeff A, Groen H, Laven JSE, Mol BWJ, Broekmans FJM, OPTIMIST study
group. Individualized versus standard FSH dosing in women starting
IVF/ICSI: an RCT. Part 1: The predicted poor responder. Hum Reprod.
2017;32(12):2496–505.
21. Somigliana E, Arnoldi M, Benaglia L, Iemmello R, Nicolosi AE, Ragni G. IVF-
ICSI outcome in women operated on for bilateral endometriomas. Hum
Reprod. 2008;23(7):1526–30.
22. Benaglia L, Pasin R, Somigliana E, Vercellini P , Ragni G, Fedele L. Unoper-
ated ovarian endometriomas and responsiveness to hyperstimulation.
Hum Reprod. 2011;26(6):1356–61.
23. Invernici D, Reschini M, Benaglia L, Somigliana E, Galati G, La Vecchia
I, Vigano’ P , Vercellini P . The impact of endometriosis on IVF efficacy:
qualitative and quantitative assessment of ovarian response and embryo
development. Reprod Biomed Online. 2022;45(2):275–81.
24. Viganò P , Reschini M, Ciaffaglione M, Cucè V, Casalechi M, Benaglia L, Ver-
cellini P , Somigliana E. Conventional IVF performs similarly in women with
and without endometriosis. J Assist Reprod Genet. 2023;40(3):599–607.
25. Casalechi M, Reschini M, Palermo MC, Di Stefano G, Vercellini P , Benaglia
L, Somigliana E, Vigano’ P . Is endometrial receptivity affected in women
with endometriosis? Results from a matched pair case-control study in
Assisted Reproductive Technology (ART) treatments. Reprod Biomed
Online. 2023;47:1–5.
26. Reschini M, Somigliana E, Busnelli A, Benaglia L, Viganò P , Vercellini P .
Peripheral estrogens in women with endometriosis undergoing IVF.
Reprod Sci. 2020;27(2):662–7.
27. Benaglia L, Busnelli A, Biancardi R, Vegetti W, Reschini M, Vercellini P ,
Somigliana E. Oocyte retrieval difficulties in women with ovarian endo-
metriomas. Reprod Biomed Online. 2018;37(1):77–84.
28. Poseidon Group (Patient-Oriented Strategies Encompassing Individual-
izeD Oocyte Number), Alviggi C, Andersen CY, Buehler K, Conforti A, De
Placido G, Esteves SC, Fischer R, Galliano D, Polyzos NP , Sunkara SK, Ubaldi
FM, Humaidan P . A new more detailed stratification of low responders
to ovarian stimulation: from a poor ovarian response to a low prognosis
concept. Fertil Steril. 2016;105(6):1452–3.
29. Shebl O, Sifferlinger I, Habelsberger A, Oppelt P , Mayer RB, Petek E, Ebner
T. Oocyte competence in in vitro fertilization and intracytoplasmic sperm
injection patients suffering from endometriosis and its possible associa-
tion with subsequent treatment outcome: a matched case-control study.
Acta Obstet Gynecol Scand. 2017;96(6):736–44.
30. Lima ML, Martins WP , Coelho Neto MA, Nastri CO, Ferriani RA, Navarro
PA. Assessment of ovarian reserve by antral follicle count in ovaries with
endometrioma. Ultrasound Obstet Gynecol. 2015;46(2):239–42.
31. Ferrero S, Scala C, Tafi E, Racca A, Venturini PL, Leone Roberti Maggiore U.
Impact of large ovarian endometriomas on the response to superovula-
tion for in vitro fertilization: A retrospective study. Eur J Obstet Gynecol
Reprod Biol. 2017;213:17–21.
32. Somigliana E, Palomino MC, Castiglioni M, Mensi L, Benaglia L, Vercellini
P , Garcia-Velasco J. The impact of endometrioma size on ovarian respon-
siveness. Reprod Biomed Online. 2020;41(2):343–8.
Page 11 of 11
Somigliana et al. Reproductive Biology and Endocrinology (2023) 21:107
33. Zeng C, Lu R, Li X, Kuai Y, Wang S, Xue Q. The presence of ovarian endo-
metrioma adversely affect ovarian reserve and response to stimulation
but not oocyte quality or IVF/ICSI outcomes: a retrospective cohort study.
J Ovarian Res. 2022;15(1):116.
34. Filippi F, Benaglia L, Paffoni A, Restelli L, Vercellini P , Somigliana E, Fedele
L. Ovarian endometriomas and oocyte quality: insights from in vitro
fertilization cycles. Fertil Steril. 2014;101(4):988-93.e1.
35. Reinblatt SL, Ishai L, Shehata F, Son WY, Tulandi T, Almog B. Effects of ovar-
ian endometrioma on embryo quality. Fertil Steril. 2011;95(8):2700–2.
36. Benaglia L, Bermejo A, Somigliana E, Faulisi S, Ragni G, Fedele L, Garcia-
Velasco JA. In vitro fertilization outcome in women with unoperated
bilateral endometriomas. Fertil Steril. 2013;99(6):1714–9.
37. Zareii A, Askary E, Ghahramani A, Chamanara K, Abadi AKH, Afzalzadeh
A. Evaluation of endometrioma size effect on ovarian reserve, embryo
quality and pregnancy outcome after in vitro fertilization cycle; a cross-
sectional study. BMC Womens Health. 2023;23(1):327.
38. Coccia ME, Rizzello F, Barone S, Pinelli S, Rapalini E, Parri C, Caracciolo D,
Papageorgiou S, Cima G, Gandini L. Is there a critical endometrioma size
associated with reduced ovarian responsiveness in assisted reproduction
techniques? Reprod Biomed Online. 2014;29(2):259–66.
39. Sanchez AM, Viganò P , Somigliana E, Panina-Bordignon P , Vercellini P ,
Candiani M. The distinguishing cellular and molecular features of the
endometriotic ovarian cyst: from pathophysiology to the potential
endometrioma-mediated damage to the ovary. Hum Reprod Update.
2014;20(2):217–30.
40. Kasapoglu I, Ata B, Uyaniklar O, Seyhan A, Orhan A, YildizOguz S, Uncu G.
Endometrioma-related reduction in ovarian reserve (ERROR): a prospec-
tive longitudinal study. Fertil Steril. 2018;110(1):122–7.
41. Benaglia L, Castiglioni M, Paffoni A, Sarais V, Vercellini P , Somigliana
E. Is endometrioma-associated damage to ovarian reserve progres-
sive? Insights from IVF cycles. Eur J Obstet Gynecol Reprod Biol.
2017;217:101–5.
42. Sanchez AM, Somigliana E, Vercellini P , Pagliardini L, Candiani M, Vigano P .
Endometriosis as a detrimental condition for granulosa cell steroidogen-
esis and development: From molecular alterations to clinical impact. J
Steroid Biochem Mol Biol. 2016;155(Pt A):35–46.
43. Komsky-Elbaz A, Raziel A, Friedler S, Strassburger D, Kasterstein E,
Komarovsky D, Ron-El R, Ben-Ami I. Conventional IVF versus ICSI in sibling
oocytes from couples with endometriosis and normozoospermic semen.
J Assist Reprod Genet. 2013;30(2):251–7.
44. Cascales A, Lledó B, Ortiz JA, Morales R, Ten J, Llácer J, Bernabeu R. Effect
of ovarian stimulation on embryo aneuploidy and mosaicism rate. Syst
Biol Reprod Med. 2021;67(1):42–9.
45. Dongye H, Ji X, Ma X, Song J, Yan L. The impact of endometriosis on
embryo quality in in-vitro fertilization/intracytoplasmic sperm injection:
a systematic review and meta-analysis. Front Med (Lausanne). 2021;2(8):
669342.
46. Sanchez AM, Pagliardini L, Cermisoni GC, Privitera L, Makieva S, Alteri A,
Corti L, Rabellotti E, Candiani M, Viganò P . Does endometriosis influence
the embryo quality and/or development? insights from a large retrospec-
tive matched cohort study. Diagnostics (Basel). 2020;10(2):83.
47. Vaiarelli A, Venturella R, Cimadomo D, Conforti A, Pedri S, Bitonti G, Iussig
B, Gentile C, Alviggi E, Santopaolo S, Zullo F, Rienzi L, Ubaldi FM. Endo-
metriosis shows no impact on the euploid blastocyst rate per cohort of
inseminated metaphase-II oocytes: a case-control study. Eur J Obstet
Gynecol Reprod Biol. 2021;256:205–10.
48. Juneau C, Kraus E, Werner M, Franasiak J, Morin S, Patounakis G, Molinaro
T, de Ziegler D, Scott RT. Patients with endometriosis have aneuploidy
rates equivalent to their age-matched peers in the in vitro fertilization
population. Fertil Steril. 2017;108(2):284–8.
49. Yan N, Yuan X, Huang S, Jie H, Wang J, Yuan Y. Ovarian endometrioma
increases the embryo aneuploid rate: an analysis of 7092 biopsied blas-
tocysts from fertile monogenetic disease carriers. BMC Womens Health.
2023;23(1):244.
50. Guo SW, Habiba M, Benagiano G. From retrograde menstruation to
endometrial determinism and a brave new world of “root treatment” of
endometriosis: destiny or a fanciful Utopia? Biomolecules. 2023;13(2):336.
51. Viganò P , Casalechi M, Vercellini P , Somigliana E. “Shadow of a Doubt”-the
pathogenic role of endometrial defects in endometriosis development
and endometriosis-associated infertility: robust demonstration of clinical
relevance is still urgently needed. Biomolecules. 2023;13(4):651.
52. Drakopoulos P , Racca A, Errázuriz J, De Vos M, Tournaye H, Blockeel C,
Pluchino N, Santos-Ribeiro S. The role of progesterone elevation in IVF.
Reprod Biol. 2019;19(1):1–5.
53. Cortés-Vazquez A, Escobosa C, Cortés-Algara AL, Moreno-García JD. Novel
insights on premature progesterone elevation: a mini-review. JBRA Assist
Reprod. 2022;26(3):531–7.
54. Viganò P , Alteri A, Busnelli A, Vanni VS, Somigliana E. Frozen IVF cycles to
circumvent the hormonal storm on endometrium. Trends Endocrinol
Metab. 2020;31(4):296–307.
55. Giuliani E, Parkin KL, Lessey BA, Young SL, Fazleabas AT. Characterization
of uterine NK cells in women with infertility or recurrent pregnancy loss
and associated endometriosis. Am J Reprod Immunol. 2014;72(3):262–9.
56. Zheng QM, Mao HI, Zhao YJ, Zhao J, Wei X, Liu PS. Risk of endometrial
polyps in women with endometriosis: a meta-analysis. Reprod Biol Endo-
crinol. 2015;17(13):103.
57. Freitag N, Pour SJ, Fehm TN, Toth B, Markert UR, Weber M, Togawa R,
Kruessel JS, Baston-Buest DM, Bielfeld AP . Are uterine natural killer
and plasma cells in infertility patients associated with endometriosis,
repeated implantation failure, or recurrent pregnancy loss? Arch Gynecol
Obstet. 2020;302(6):1487–94.
58. Kodaman PH. Current strategies for endometriosis management. Obstet
Gynecol Clin North Am. 2015;42(1):87–101.
59. de Boer A, Rees CO, Mischi M, van Vliet H, Huirne J, Schoot BC. The influ-
ence of uterine abnormalities on uterine peristalsis in the nonpregnant
uterus: a systematic review. J Endometriosis Uterine Dis. 2023;26:100038.
60. Vernaeve V, Reis Soares S, Budak E, Bellver J, Remohi J, Pellicer A. Fac-
teurs cliniques et résultats du don d’ovocytes [Clinical factors associ-
ated with the outcome of oocyte donation]. Gynecol Obstet Fertil.
2007;35(10):1015–23.
61. Bishop LA, Gunn J, Jahandideh S, Devine K, Decherney AH, Hill MJ. Endo-
metriosis does not impact live-birth rates in frozen embryo transfers of
euploid blastocysts. Fertil Steril. 2021;115(2):416–22.
62. Blank C, Deboever C, Decroos E, DeCroo I, Tilleman K, De Sutter P , Mischi
M, Schoot BC. Impaired implantation in endometriosis compared with
couples with male subfertility after transfer of equal quality embryos: a
matched cohort study. Reprod Biomed Online. 2021;42:165–74.
63. Zhou L, Wang L, Geng Q, Zhang H, Xu S, Diao L, Zeng Y, Mo M, Li L.
Endometriosis is associated with a lowered cumulative live birth rate: a
retrospective matched cohort study including 3071 in vitro fertilization
cycles. J Reprod Immunol. 2022;151:103631.
64. Zimmermann A, Faust C, Miquel L, Berbis J, Perrin J, Courbiere B. Impact
of moderate-to-severe endometriosis on IVF cumulative live birth
rate: a retrospective matched cohort study. Reprod Biomed Online.
2023;4:103186.
65. Budak E, Garrido N, Soares SR, Melo MA, Meseguer M, Pellicer A, Remohí
J. Improvements achieved in an oocyte donation program over a
10-year period: sequential increase in implantation and pregnancy
rates and decrease in high-order multiple pregnancies. Fertil Steril.
2007;88(2):342–9.
66. Metelli S, Chaimani A. Challenges in meta-analyses with observational
studies. Evid Based Ment Health. 2020;23(2):83–7.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.